Junlong Zhuang, PhD

CONTACT

Hongqian Guo, PhD

CONTACT

Lead Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

•Histopathologic confirmed unresectable advanced or metastatic bladder cancer, except for those with squamous differentiation, glandular differentiation or both;
•Failure of first-line treatment;
•There is at least one measurable lesion according to RECIST 1.1;
•Archived tumor tissue samples or tumor biopsies must be provided;
•ECOG score of 0-1 an an estimated survival of at least 6 months;
•Adequate organ function;
•Patients voluntarily participated in this study, signed the informed consent form, and had good compliance;
•Women with fertility must consent to contraception during the study and for 6 months after the last dose of study drug.

•Patients who received platinum-based chemotherapy after failure of first-line treatment;
•Patients who received platinum-based chemotherapy withnin a 24 month before this trial;
•Those who have received other anti-tumor treatment or participated in other clinical studies within 4 weeks before the start of the study, or have not recovered from the last toxicity (except grade 2 hair loss and grade 1 neurotoxicity);
•Concomitant disease such as uncontrolled hypertension or diabetes, renal inadequacy, myocardial infarction, severe angina;
•Female subjects who are pregnant, breastfeeding or planning to become pregnant during the study;
•Patients with serious physical or mental illnesses.